Beam Therapeutics (NASDAQ: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. The company's proprietary base editing technology enables a new class of genetic medicines that target a single base in the genome without making a double-stranded break in the DNA. Beam is focused on developing therapies for serious diseases with a broad portfolio of programs in hematology, immunology, oncology, and genetic diseases.
Serves as the central hub for corporate leadership, research and development, strategic planning, and administrative operations.
Located in the heart of Kendall Square, a prominent biotech innovation hub, providing access to a rich ecosystem of talent and collaboration. Modern laboratory and office facilities designed to foster cutting-edge research.
A dynamic, science-driven, and collaborative environment focused on innovation and making a difference in patients' lives. Emphasis on teamwork, scientific rigor, and a patient-centric approach.
The Cambridge HQ is strategically positioned to leverage the dense concentration of academic institutions, research organizations, and biotech companies in the Boston area, facilitating partnerships and talent acquisition.
Beam Therapeutics' primary operations, including research, development, and manufacturing, are based in the United States (Cambridge, MA and Durham, NC). While they may engage in global clinical trials and collaborations with international partners and institutions to advance their gene editing therapies, their physical office and manufacturing footprint is currently concentrated in the US. Their therapeutic candidates, if successful, would aim for global impact on patients with serious diseases.
238 Main St
Cambridge
MA
United States
Address: 100 Resilience Way, Durham, NC 27703
Located in Research Triangle Park (RTP), a major hub for life sciences and biomanufacturing, providing access to specialized talent and infrastructure for scalable manufacturing.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Beam Therapeutics' leadership includes:
Beam Therapeutics has been backed by several prominent investors over the years, including:
In the past 12 months, Beam Therapeutics saw a key departure with its President and Chief Scientific Officer. The CEO has assumed interim leadership of the research organization. No major external C-suite hires have been publicly announced during this period.
Discover the tools Beam Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Beam Therapeutics likely utilizes common corporate email formats. Based on industry patterns and available data, one of the most probable formats is the first initial followed by the last name.
[first_initial][last]@beamtx.com
Format
jevans@beamtx.com
Example
80%
Success rate
Beam Therapeutics • May 9, 2024
Beam Therapeutics announced its Q1 2024 financial results, highlighting progress in its clinical programs, including BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency. The company also provided updates on its pipeline and manufacturing capabilities....more
Beam Therapeutics • April 8, 2024
Beam announced upcoming presentations at ASGCT 2024, showcasing preclinical data for its in vivo base editing programs, including BEAM-302 for AATD and BEAM-301 for GSDIa....more
Beam Therapeutics SEC Filing (8-K) • January 3, 2024
Beam Therapeutics announced that Giuseppe Ciaramella, Ph.D., President and Chief Scientific Officer, departed from the company effective January 3, 2024. John Evans, Chief Executive Officer, assumed interim leadership of the company’s research organization....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Beam Therapeutics, are just a search away.